Morphological characterization of receptor activator of NFκB ligand (RANKL) and IL-1β expression in rodent collagen-induced arthritis

Scandinavian Journal of Immunology

Volumn 62, Issue 1, 2005, Pages 55-62

  Weiss, R J ^a   Harris, H Erlandsson ^a   Wick, M C ^a   Wretenberg, P ^a   Stark, A ^a   Palmblad, K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLLAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1;

ANIMAL TISSUE; ARTICLE; BONE EROSION; CARTILAGE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; JOINT DESTRUCTION; MALE; MORPHOLOGICAL TRAIT; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE AND BONES; CARRIER PROTEINS; CARTILAGE, ARTICULAR; CYTOKINES; INTERLEUKIN-1; MALE; MEMBRANE GLYCOPROTEINS; RANK LIGAND; RATS; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 22644439769     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01632.x     Document Type: Article

References (30)

1. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143-51.
2. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315.
3. Feldman M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-71.
4. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996;87:2095-147.
5. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
6. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
7. Cernanec J, Guilak F, Weinberg JB, Pisetsky DS, Femor B. Influence of hypoxia and reoxygenation on cytokine-induced production of proinflammatory mediators in articular cartilage. Arthritis Rheum 2002;46:968-75.
8. Jimi E, Nakamura I, Duong LT et al. Interleukin 1 induces multi-nucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999;247:84-93.
9. Gravallese EM, Manning C, Tsay A et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
10. Crotti TN, Smith MD, Weedon H et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002;61:1047-54.
11. Romas E, Sims NA, Hards DK et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002;161:1419-27.
12. Redlich K, Hayer S, Maier A et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-92.
13. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-a in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6.
14. Trentham DE. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum 1982;25:911-6.
15. Larsson P, Kleinau S, Holmdahl R, Klarekog L. Homologous type II collagen-induced arthritis in rats. Characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis Rheum 1990;33:693-701.
16. Åkerlund K, Erlandsson Harris H, Tracey KJ et al. Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-a) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats. Clin Exp Immunol 1999;115:32-41.
17. Ahmed M, Bjurholm A, Schultzberg M, Theodorsson E, Kreicbergs A. Increased levels of substance P and calcitonin gene-related peptide in rat adjuvant arthritis. A combined immunohistochemical and radioimmunoassay analysis. Arthritis Rheum 1995;38:699-709.
18. Palmblad K, Erlandsson-Harris H, Tracey KJ, Andersson U. Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis: a therapeutic study using a macrophage deactivating compound. Am J Pathol 2001;158:491-500.
19. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-a blockade only ameliorates joint inflammation. J Immunol 1999;163:5049-55.
20. Cunnane G, Björk L, Ulfgren AK et al. Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements. Ann Rheum Dis 1999;58:493-9.
21. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol 1998;2:466-71.
22. van de Loo AA, van den Berg WB. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990;49:238-45.
23. Komuro H, Olee T, Kuhn K et al. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum 2001;44:2768-76.
24. Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
25. Takayanagi H, Oda H, Yamamoto S et al. A new mechanism of bone destruction in rheumatoid ardiritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997;240:279-86.
26. Fujikawa Y, Sabokbar A, Neale SD, Itonaga I, Torisu T, Adianasou NA. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1-3-6, and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone 2001;28:261-7.
27. O'Gradaigh D, Ireland D, Bord S, Comston JE. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004;63:354-9.
28. Harris HE, Liljestrom M, Klareskog L. Characterization of adhesion molecule expression in the pathogenesis of homologous collagen-induced arthritis in the DA rat. Clin Immunol Immunopathol 1997;85:40-6.
29. Klareskog L, Forsum U, Wigren A, Wigzell H. Relationship between HLA-DR-expressing cells and T lymphocytes of different subsets in rheumatoid synovial tissue. Scand J Immunol 1981;15:501-7.
30. Smith MD, Barg E, Weedon H et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum Dis 2003;62:303-7.